⚑Your ready-to-use recruitment solution: IRB-compliant, SEO-optimized website that automatically routes qualified patient leads to your clinical study (14-day free trial, then $44/mo)

NCT06393712RECRUITINGIRB Ready

A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy

(cAPPricorn-1)

Sponsored by Alnylam Pharmaceuticals

Quick Self-Assessment

See if you qualify and express your interest

Preparing your pre-screening questions...
πŸ“Š
1 of 200 participants interested
1% interest

Express Your Interest Today

Interested in learning more? Complete the form below.

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Advance Medical Science

    Contribute to groundbreaking research

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel (varies by study)

  • Help Others

    Benefit future patients

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3In-person assessment if eligible
  4. 4Begin participation

About This Study

The purpose of the study is to evaluate the effect of ALN-APP on measures of CAA disease progression and to characterize the safety, tolerability, and pharmacodynamics (PD) of ALN-APP in adult patients with sporadic CAA (sCAA) and Dutch-type CAA (D-CAA). The study will be conducted over 2 periods: a 24-month double-blind treatment period and an optional 18-month open-label extension (OLE) period.

Who Can Participate

Inclusion Criteria

(sporadic CAA patients):
Is 50 years or older
Has probable CAA per the Boston Criteria Version 2.0 Inclusion Criteria (Dutch-type CAA patients):
Is 30 years or older
Has known E693Q amyloid precursor protein (APP) gene mutation for Dutch-type CAA

Exclusion Criteria

Moderate or severe stage Alzheimer's disease (AD) or significant cognitive impairment (CI)
Has a history of previous clinical intracerebral hemorrhage (ICH) with onset less than 90 days prior to anticipated randomization in the study
Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>3Γ—upper limit of normal (ULN) at Screening
Has estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73m\^2 at Screening
Has recently received an investigational agent
Has had treatment with amyloid-targeting antibody Note: other protocol defined inclusion / exclusion criteria apply

❓ Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility during the screening process.

Study Details

πŸ“‹

Study Type

INTERVENTIONAL

πŸ‘₯

Target Enrollment

200 participants

⚧

Gender

ALL

🏒

Sponsor

Alnylam Pharmaceuticals

Study Locations

Choose your preferred location or select flexible during enrollment

RECRUITING

Palo Alto

California

Location available
View Palo Alto location page
RECRUITING

Sacramento

California

Location available
View Sacramento location page
RECRUITING

San Francisco

California

Location available
View San Francisco location page
RECRUITING

Gainesville

Florida

Location available
View Gainesville location page
RECRUITING

Jacksonville

Florida

Location available
View Jacksonville location page
RECRUITING

Naples

Florida

Location available
View Naples location page
RECRUITING

Chicago

Illinois

Location available
View Chicago location page
RECRUITING

Lexington

Kentucky

Location available
View Lexington location page
RECRUITING

New Orleans

Louisiana

Location available
View New Orleans location page

πŸ“ And 15 more locations available

Frequently Asked Questions

Q:What is a clinical trial?

A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.

Q:Will I be compensated?

Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.

Q:Will I receive a placebo instead of treatment?

When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.

Q:Can I leave a trial if I change my mind?

Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.

Q:How long does a clinical trial last?

Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.

Still have questions? Our study coordinators are here to help.

Ready to Make a Difference?

Express your interest in this groundbreaking clinical trial

πŸ”’ Secure Β· πŸ₯ Expert Care

Looking for Cerebral Amyloid Angiopathy Treatment in Palo Alto?

Join others in California exploring innovative treatment options through clinical research

Cerebral Amyloid Angiopathy Treatment Options in Palo Alto, California

If you're searching for Cerebral Amyloid Angiopathy treatment in Palo Alto, participating in a clinical research study may provide access to innovative approaches under expert medical supervision. This study is actively recruiting participants in Palo Alto, Sacramento, San Francisco and surrounding areas.

Clinical trials offer participants the opportunity to receive cutting-edge treatments while contributing to medical research that may help future patients with Cerebral Amyloid Angiopathy. All study-related care is provided at no cost to participants.

Local Sites
3 locations in California
Now Enrolling
Up to 200 participants
Quick Start
Screening available now

Why Consider a Clinical Trial for Cerebral Amyloid Angiopathy?

Potential Benefits

  • βœ“Access to new treatment approaches before public availability
  • βœ“Close monitoring by experienced medical professionals
  • βœ“Study-related care provided at no cost
  • βœ“Contribute to medical research for Cerebral Amyloid Angiopathy

What to Expect

  • β†’Initial screening to determine eligibility
  • β†’Regular check-ups and monitoring visits
  • β†’Possible compensation for time and travel
  • β†’You can withdraw at any time

Frequently Asked Questions About This Cerebral Amyloid Angiopathy Study

Important Clinical Trial Information

This information is provided for educational purposes and does not constitute medical advice. Clinical trial participation involves potential risks and benefits. Eligibility requirements apply and will be assessed during the screening process.

Study identifier: NCT06393712. For complete study details, visit ClinicalTrials.gov. Always consult with your healthcare provider before making decisions about your medical care or participating in clinical research.